Screener
Vera Therapeutics VERA Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchase of property and equipment | (23) | (187) |
| Purchase of marketable securities | (210,561) | (89,992) |
| Proceeds from maturities of marketable securities | 87,918 | 106,246 |
| Net cash (used in) provided by investing activities | (137,816) | 15,317 |
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options and employee stock purchase plan | 3,942 | 1,533 |
| Net cash provided by financing activities | 3,942 | 1,533 |
| Net decrease in cash and cash equivalents | (240,374) | (37,556) |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's investing cash flow?
- Vera Therapeutics (VERA) reported investing cash flow of -$137.82M in Q1 2026.
- How has Vera Therapeutics's investing cash flow changed year-over-year?
- Vera Therapeutics's investing cash flow decreased by 999.8% year-over-year, from $15.32M to -$137.82M.
- What is the long-term trend for Vera Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Vera Therapeutics's investing cash flow has grown at a 579.8% compound annual growth rate (CAGR), from -$4.2M to $194.29M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Vera Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude